adMare Industry Builder Series featuring Dr. Renata Oballa: From the drug discovery to the patient: the success of Chinook Therapeutics

Join us on Thursday, November 21st, for an adMare Industry Builder Series webinar featuring Dr. Renata Oballa, VP Research Operations and Vancouver site Head, where she will discuss the story behind the acquisition success of Chinook Therapeutics by Novartis for USD 3.5G B$ US as well as a Chinook drug discovery story for a rare kidney disease.

Chinook has developed precision medicines for kidney diseases with two late-stage assets in clinical development to treat Immunoglobulin A Nephropathy (IgAN), atrasentan and zigakibart (BION-1301), as well as earlier stage research and development programs, all designed to provide new therapies for patients with kidney disease. 

Dr Renata Oballa and her team have been trailblazer in this exploration of innovative treatments that converge scientific and translational breakthroughs to enable the field of small molecule and biologic medicines to treat kidney diseases and beyond.

About Dr. Renata Oballa

Dr. Renata Oballa is VP at Chinook Therapeutics, a company she co-founded and where she heads up research operations and is the Vancouver site Head. Chinook was acquired in 2023 by Novartis for their kidney assets. The research group at Chinook has recently spun out to form Borealis BioSciences and Renata will act as an advisor to this team.

Prior to Chinook, she was Head of chemistry at Inception Sciences Canada and Director of chemistry at Xenon Pharmaceuticals and Merck. Her undergraduate degree was in chemistry and biochemistry at UBC, she received her Ph.D. in synthetic organic chemistry under the supervision of Dr. Edward Piers (UBC) and conducted post-doctoral research in natural product total synthesis in the laboratory of Dr. Ian Paterson (University of Cambridge, UK).